919-797-1146 info@aimmaxrx.com

 

 

Development 

An ophthalmic formulation with enhanced penetration, potent anti-inflammatory activity and reduced dosing frequency for the treatment of inflammation and pain post ocular surgery under the regulatory 505(b)(2) pathway. Currently in Phase 3 clinical development.

 

Research

Discovery and early development of novel or improved anti-infectives against resistant bacteria and other microorganisms.